Recent Updates
Recently added Catalysts
IRWD Positive Sentiment

Ironwood Pharmaceuticals Raises Full-Year 2026 Financial Guidance Driven by Continued LINZESS U.S. Net Sales Growth and Strong Third Quarter Financial Performance

Thursday, November 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Ironwood Pharmaceuticals announced strong third quarter results for 2026, driven by continued growth in U.S. net sales of LINZESS. The company raised its financial guidance for the full year, reflecting confidence in its strategic priorities. This marks the third consecutive strong quarter for Ironwood.

Market Sentiment Analysis

POSITIVE FACTORS

  • Ironwood reported strong third quarter results.
  • LINZESS U.S. net sales continue to grow.
  • The company raised its full-year 2026 financial guidance.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+57%
120-day peak, hindsight
Typical move
3.8%
average across 2 past catalysts
Lead asset
Apraglutide
Phase 1 · Hepatic Impairment

Full Press Release Details

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its third quarter 2026 results and recent business performance update. “Ironwood delivered a third consecutive strong quarter as we continue focused execution of our three strategic priorities: maximize LINZESS, advance apraglutide and deliver sustained profits and cas

Frequently Asked Questions

What financial guidance did Ironwood raise?

Ironwood raised its full-year financial guidance for 2026.

What contributed to Ironwood's strong Q3 results?

Continued growth in U.S. net sales of LINZESS contributed to the results.

How many strong quarters has Ironwood reported?

Ironwood reported its third consecutive strong quarter.

What are Ironwood's strategic priorities?

The priorities include maximizing LINZESS and advancing apraglutide.

ShareAdd on Google
Tags: IRWD Ironwood Pharmaceuticals LINZESS financial guidance Q3 results
Last updated: Nov 5, 2026

Biotech snapshot

Cash runway
$79M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ApraglutidePhase 1
Hepatic Impairment →

Catalyst track record

+57%
best trade around IRWD's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for IRWD.

See every catalyst's timing & PoA →